Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070008/S183

Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T

Biotronik, Inc. · Decision date Oct 13, 2026

MEDTECHLEDGER EXPLANATIONP070008/S183

What did the FDA decide?

FDA's decision OK30 covers PMA supplement P070008/S183 for Biotronik's Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP and Enitra 8 HF-T cardiac resynchronization pacemakers (product code NKE). The supplement carries a 30-day notice for a process change by a manufacturer, sterilizer, packager or supplier: a change to the rework process for the manufacturing of the housing for pulse generators and ICDS. The source does not specify which rework steps, equipment, validation criteria or supplier changed.

The P070008 identifier ties the notice to an existing PMA rather than a new system approval, and the source does not state the original scope of that approval. The notice reports the manufacturer's stated purpose for a manufacturing-process change; it is not independent proof of safety or clinical effectiveness. The decision date is 2026-10-13, listed as OK30.

FDA approval order statement

a change to the rework process for the manufacturing of the housing for pulse generators and ICDS
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P070008/S183
Regulatory pathway
PMA supplement
Product code
NKE
Decision code
OK30
Decision date
Oct 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).

Product code
NKE
FDA device class
3

For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P070008 · Original PMA

    STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD

  2. P070008/S183 received

    Application receipt date recorded by FDA.

  3. P070008/S172 · Related supplement

    Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H

  4. P070008/S182 · Related supplement

    Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-

  5. P070008/S181 · Related supplement

    Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr

  6. P070008/S183 · FDA decision

    30-Day Notice

  7. P070008/S184 · Related supplement

    Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR

Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070008

Explore the linked device profile

Other records with product code NKE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records